Skip to main navigation Skip to search Skip to main content

Metabolic surgery versus conventional therapy in type 2 diabetes

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish
Pages (from-to)256-257
Number of pages2
JournalThe Lancet
Volume397
Issue number10271
DOIs
Publication statusPublished (in print/issue) - 23 Jan 2021

Bibliographical note

Funding Information:
CWlR declares grant funding from Science Foundation Ireland (12/YI/B2480), the Health Research Board (USIRL-2016-2), and the Irish Research Council (IRCLA/2017/234) in the area of type 2 diabetes. CWlR serves on advisory boards for Novo Nordisk, Herbalife, Boehringer Ingelheim, Johnson & Johnson, Keyron, AnaBio, and Sanofi, outside of the area of work commented on here. ADM declares no competing interests.

Funding

CWlR declares grant funding from Science Foundation Ireland (12/YI/B2480), the Health Research Board (USIRL-2016-2), and the Irish Research Council (IRCLA/2017/234) in the area of type 2 diabetes. CWlR serves on advisory boards for Novo Nordisk, Herbalife, Boehringer Ingelheim, Johnson & Johnson, Keyron, AnaBio, and Sanofi, outside of the area of work commented on here. ADM declares no competing interests.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Bariatric Surgery
  • Diabetes Mellitus, Type 2/drug therapy
  • Follow-Up Studies
  • Glycated Hemoglobin A/analysis
  • Humans

Cite this